Therawis

Executive Summary

Therawis is a German diagnostics company founded in 2017 and headquartered in Munich, specializing in theranostics for oncology. The company combines innovative diagnostic tools with targeted therapeutics to enable personalized cancer treatment. Certified under ISO 9001:2015, Therawis operates across diagnostics, clinical services, and technology development. While specific financial details and clinical pipelines are undisclosed, the company's focus on theranostics positions it in a rapidly growing market driven by precision medicine trends. Therawis's private status suggests it is likely in early to mid-stage development, with potential for partnerships or product launches in the near term.

Upcoming Catalysts (preview)

• Q4 2026CE Mark Approval for Lead Theranostic Product60% success
• Q1 2027Pharma Partnership for Companion Diagnostic Development70% success
• Q2 2027Publication of Clinical Validation Study Results80% success